Edward W Cowen1, Josephine C Nguyen2, Daniel D Miller3, Diana McShane4, Sarah T Arron3, Neil S Prose4, Maria L Turner2, Lindy P Fox3. 1. Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: cowene@mail.nih.gov. 2. Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 3. Department of Dermatology, University of California, San Francisco, California. 4. Department of Dermatology, Duke University Medical Center, Durham, North Carolina.
Abstract
BACKGROUND: Voriconazole is a broad-spectrum antifungal agent associated with photosensitivity and accelerated photoaging. A possible link with aggressive squamous cell carcinoma (SCC) has also been reported. OBJECTIVE: We sought to determine the incidence and frequency of cutaneous SCC among patients undergoing long-term treatment with voriconazole who also manifest features of chronic phototoxicity. METHODS: We conducted a retrospective review of patients who developed one or more squamous cell neoplasms during long-term treatment with voriconazole at 3 academic dermatology centers. RESULTS: A total of 51 cutaneous SCC were identified in 8 patients (median age 34.5 years, range 9-54) treated with chronic voriconazole (median duration 46.5 months, range 13-60). Underlying diagnoses included graft-versus-host disease, HIV, and Wegener granulomatosis. Signs of chronic phototoxicity and accelerated photoaging included erythema, actinic keratoses, and lentigo formation. LIMITATIONS: The retrospective nature of the study cannot determine the true population risk of SCC associated with voriconazole therapy. A prospective cohort study is needed. CONCLUSION: A high index of suspicion for photosensitivity and SCC may be warranted with chronic voriconazole use when used in the setting of concurrent immunosuppression.
BACKGROUND:Voriconazole is a broad-spectrum antifungal agent associated with photosensitivity and accelerated photoaging. A possible link with aggressive squamous cell carcinoma (SCC) has also been reported. OBJECTIVE: We sought to determine the incidence and frequency of cutaneous SCC among patients undergoing long-term treatment with voriconazole who also manifest features of chronic phototoxicity. METHODS: We conducted a retrospective review of patients who developed one or more squamous cell neoplasms during long-term treatment with voriconazole at 3 academic dermatology centers. RESULTS: A total of 51 cutaneous SCC were identified in 8 patients (median age 34.5 years, range 9-54) treated with chronic voriconazole (median duration 46.5 months, range 13-60). Underlying diagnoses included graft-versus-host disease, HIV, and Wegener granulomatosis. Signs of chronic phototoxicity and accelerated photoaging included erythema, actinic keratoses, and lentigo formation. LIMITATIONS: The retrospective nature of the study cannot determine the true population risk of SCC associated with voriconazole therapy. A prospective cohort study is needed. CONCLUSION: A high index of suspicion for photosensitivity and SCC may be warranted with chronic voriconazole use when used in the setting of concurrent immunosuppression.
Authors: Elizabeth M Kang; Betty E Marciano; SukSee DeRavin; Kol A Zarember; Steven M Holland; Harry L Malech Journal: J Allergy Clin Immunol Date: 2011-04-17 Impact factor: 10.793
Authors: Jennifer T Huang; Carrie C Coughlin; Elena B Hawryluk; Kristen Hook; Stephen R Humphrey; Lacey Kruse; Leslie Lawley; Hasan Al-Sayegh; Wendy B London; Ashfaq Marghoob; Thuy L Phung; Elena Pope; Pedram Gerami; Birgitta Schmidt; Sarah Robinson; Diana Bartenstein; Eman Bahrani; Meera Brahmbhatt; Lily Chen; Ellen Haddock; Danny Mansour; Julie Nguyen; Tom Raisanen; Gary Tran; Kate Travis; Zachary Wolner; Lawrence F Eichenfield Journal: J Pediatr Date: 2019-05-15 Impact factor: 4.406
Authors: Mamina M Turegano; Chyi-Chia R Lee; Harry L Malech; Suk S De Ravin; Edward W Cowen; Isaac Brownell Journal: J Am Acad Dermatol Date: 2014-03 Impact factor: 11.527